Cargando…

A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Meyerhardt, Jeffrey A, Grady, Michele M, Lowe, Jamie N, Gargano, Michele A, Huhn, Richard D, Braun, Ada H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288729/ http://dx.doi.org/10.1186/2051-1426-2-S3-P71

Ejemplares similares

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
por: Thomas, M., et al.
Publicado: (2017)

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
por: Chan, Anissa S. H., et al.
Publicado: (2016)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
por: Chan, Anissa S. H., et al.
Publicado: (2022)

Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype
por: Fraser, Kathryn, et al.
Publicado: (2015)

Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype
por: Chan, Anissa SH, et al.
Publicado: (2014)

Tracés des circuits imprimés
por: Dunand, Philippe
Publicado: (2000)

Spécification technique pour circuits imprimes
Publicado: (1986)

Specification sur la realisation des circuits imprimes
por: Coudert, G
Publicado: (1974)

Specification sur la realisation des circuits imprimes
Publicado: (1978)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
por: Barmettler, Hanna, et al.
Publicado: (2012)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

PGG.Han: the Han Chinese genome database and analysis platform
por: Gao, Yang, et al.
Publicado: (2020)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer
por: Mineur, L., et al.
Publicado: (2020)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Instructions pour l'elaboration des circuits imprimes et documents annexes
por: Redard, J
Publicado: (1973)

Specification pour l'equipement des circuits imprimes et des tiroirs
por: Coudert, G
Publicado: (1974)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

High Capability of Pentagalloylglucose (PGG) in Inhibiting Multiple Types of Membrane Ionic Currents
por: Chang, Wei-Ting, et al.
Publicado: (2020)

PGG.MHC: toward understanding the diversity of major histocompatibility complexes in human populations
por: Zhao, Xiaohan, et al.
Publicado: (2022)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer
por: Chen, Baomin, et al.
Publicado: (2020)

Synthesis, characterization, and in vivo efficacy evaluation of PGG–docetaxel conjugate for potential cancer chemotherapy
por: Yang, Danbo, et al.
Publicado: (2012)

PGG.Population: a database for understanding the genomic diversity and genetic ancestry of human populations
por: Zhang, Chao, et al.
Publicado: (2018)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Remarques et avis de !’Atelier Electronique: sur l’utilisation des circuits imprimés
por: Mary, M
Publicado: (1961)

PGG.SNV: understanding the evolutionary and medical implications of human single nucleotide variations in diverse populations
por: Zhang, Chao, et al.
Publicado: (2019)

The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
por: Wu, De-Wei, et al.
Publicado: (2017)

Remarques et avis de l'atelier électronique sur l'utilisation des circuits imprimés
por: Mary, M
Publicado: (1961)

Cannot write session to /tmp/vufind_sessions/sess_lgeq0aia26jge653q80aoib4nm